Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: RANBP2

Gene summary for RANBP2

Gene summary.

Gene information	Species	Human
	Gene symbol	RANBP2
	Gene ID	5903
	Gene name	RAN binding protein 2
	Gene Alias	ADANE
	Cytomap	2q13
	Gene Type	protein-coding
	GO ID	GO:0000413
	UniProtAcc	P49792

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
5903	RANBP2	LZE4T	Human	Esophagus	ESCC	3.73e-17	5.99e-01	0.0811
5903	RANBP2	LZE7T	Human	Esophagus	ESCC	1.54e-10	8.92e-01	0.0667
5903	RANBP2	LZE20T	Human	Esophagus	ESCC	2.24e-09	1.72e-01	0.0662
5903	RANBP2	LZE24T	Human	Esophagus	ESCC	3.68e-14	4.31e-01	0.0596
5903	RANBP2	LZE21T	Human	Esophagus	ESCC	5.11e-06	1.26e-01	0.0655
5903	RANBP2	P1T-E	Human	Esophagus	ESCC	1.41e-11	3.67e-01	0.0875
5903	RANBP2	P2T-E	Human	Esophagus	ESCC	1.90e-33	5.12e-01	0.1177
5903	RANBP2	P4T-E	Human	Esophagus	ESCC	7.81e-12	4.11e-01	0.1323
5903	RANBP2	P5T-E	Human	Esophagus	ESCC	3.10e-20	2.64e-01	0.1327
5903	RANBP2	P8T-E	Human	Esophagus	ESCC	2.69e-22	3.96e-01	0.0889
5903	RANBP2	P9T-E	Human	Esophagus	ESCC	6.25e-13	3.39e-01	0.1131
5903	RANBP2	P10T-E	Human	Esophagus	ESCC	1.09e-43	7.94e-01	0.116
5903	RANBP2	P11T-E	Human	Esophagus	ESCC	3.88e-12	6.18e-01	0.1426
5903	RANBP2	P12T-E	Human	Esophagus	ESCC	3.65e-24	4.76e-01	0.1122
5903	RANBP2	P15T-E	Human	Esophagus	ESCC	1.56e-23	6.92e-01	0.1149
5903	RANBP2	P16T-E	Human	Esophagus	ESCC	8.95e-22	4.87e-01	0.1153
5903	RANBP2	P20T-E	Human	Esophagus	ESCC	4.25e-15	2.65e-01	0.1124
5903	RANBP2	P21T-E	Human	Esophagus	ESCC	1.16e-32	7.03e-01	0.1617
5903	RANBP2	P22T-E	Human	Esophagus	ESCC	4.24e-24	2.30e-01	0.1236
5903	RANBP2	P23T-E	Human	Esophagus	ESCC	3.00e-20	4.29e-01	0.108

Page: 1 2 3 4 5 6 7

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00106752	Liver	HCC	regulation of cellular carbohydrate metabolic process	88/7958	146/18723	1.08e-05	1.24e-04	88
GO:00004131	Liver	HCC	protein peptidyl-prolyl isomerization	31/7958	42/18723	3.83e-05	3.80e-04	31
GO:004426221	Liver	HCC	cellular carbohydrate metabolic process	153/7958	283/18723	5.27e-05	5.00e-04	153
GO:00160512	Liver	HCC	carbohydrate biosynthetic process	113/7958	202/18723	7.64e-05	6.83e-04	113
GO:0016925	Liver	HCC	protein sumoylation	34/7958	53/18723	1.20e-03	6.68e-03	34
GO:00061111	Liver	HCC	regulation of gluconeogenesis	31/7958	48/18723	1.66e-03	8.71e-03	31
GO:003367411	Liver	HCC	positive regulation of kinase activity	230/7958	467/18723	1.72e-03	8.95e-03	230
GO:00432551	Liver	HCC	regulation of carbohydrate biosynthetic process	56/7958	97/18723	1.75e-03	9.11e-03	56
GO:1903299	Liver	HCC	regulation of hexokinase activity	9/7958	11/18723	9.51e-03	3.60e-02	9
GO:007259416	Prostate	BPH	establishment of protein localization to organelle	142/3107	422/18723	4.01e-18	1.31e-15	142
GO:000645716	Prostate	BPH	protein folding	85/3107	212/18723	2.37e-16	4.74e-14	85
GO:003450410	Prostate	BPH	protein localization to nucleus	98/3107	290/18723	4.78e-13	4.35e-11	98
GO:000691315	Prostate	BPH	nucleocytoplasmic transport	92/3107	301/18723	1.09e-09	4.84e-08	92
GO:005116915	Prostate	BPH	nuclear transport	92/3107	301/18723	1.09e-09	4.84e-08	92
GO:000640316	Prostate	BPH	RNA localization	65/3107	201/18723	2.76e-08	8.13e-07	65
GO:003367416	Prostate	BPH	positive regulation of kinase activity	122/3107	467/18723	8.59e-08	2.14e-06	122
GO:001703810	Prostate	BPH	protein import	62/3107	206/18723	9.72e-07	1.77e-05	62
GO:00182055	Prostate	BPH	peptidyl-lysine modification	96/3107	376/18723	5.70e-06	8.39e-05	96
GO:00511708	Prostate	BPH	import into nucleus	48/3107	159/18723	1.42e-05	1.85e-04	48
GO:005123610	Prostate	BPH	establishment of RNA localization	49/3107	166/18723	2.26e-05	2.71e-04	49

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa05014210	Esophagus	ESCC	Amyotrophic lateral sclerosis	266/4205	364/8465	1.31e-20	2.20e-18	1.13e-18	266
hsa0301321	Esophagus	ESCC	Nucleocytoplasmic transport	89/4205	108/8465	1.20e-12	2.37e-11	1.21e-11	89
hsa032509	Esophagus	ESCC	Viral life cycle - HIV-1	54/4205	63/8465	2.01e-09	2.17e-08	1.11e-08	54
hsa0501438	Esophagus	ESCC	Amyotrophic lateral sclerosis	266/4205	364/8465	1.31e-20	2.20e-18	1.13e-18	266
hsa0301331	Esophagus	ESCC	Nucleocytoplasmic transport	89/4205	108/8465	1.20e-12	2.37e-11	1.21e-11	89
hsa0325014	Esophagus	ESCC	Viral life cycle - HIV-1	54/4205	63/8465	2.01e-09	2.17e-08	1.11e-08	54
hsa0501422	Liver	HCC	Amyotrophic lateral sclerosis	252/4020	364/8465	8.85e-18	7.41e-16	4.12e-16	252
hsa03013	Liver	HCC	Nucleocytoplasmic transport	81/4020	108/8465	4.28e-09	6.83e-08	3.80e-08	81
hsa032502	Liver	HCC	Viral life cycle - HIV-1	46/4020	63/8465	3.25e-05	1.88e-04	1.04e-04	46
hsa0501432	Liver	HCC	Amyotrophic lateral sclerosis	252/4020	364/8465	8.85e-18	7.41e-16	4.12e-16	252
hsa030131	Liver	HCC	Nucleocytoplasmic transport	81/4020	108/8465	4.28e-09	6.83e-08	3.80e-08	81
hsa0325011	Liver	HCC	Viral life cycle - HIV-1	46/4020	63/8465	3.25e-05	1.88e-04	1.04e-04	46
hsa0501426	Prostate	BPH	Amyotrophic lateral sclerosis	151/1718	364/8465	3.37e-21	1.01e-19	6.25e-20	151
hsa032504	Prostate	BPH	Viral life cycle - HIV-1	24/1718	63/8465	8.32e-04	3.98e-03	2.46e-03	24
hsa05014111	Prostate	BPH	Amyotrophic lateral sclerosis	151/1718	364/8465	3.37e-21	1.01e-19	6.25e-20	151
hsa0325012	Prostate	BPH	Viral life cycle - HIV-1	24/1718	63/8465	8.32e-04	3.98e-03	2.46e-03	24
hsa0501427	Prostate	Tumor	Amyotrophic lateral sclerosis	155/1791	364/8465	3.41e-21	1.13e-19	6.99e-20	155
hsa0325021	Prostate	Tumor	Viral life cycle - HIV-1	25/1791	63/8465	6.13e-04	3.07e-03	1.91e-03	25
hsa0501436	Prostate	Tumor	Amyotrophic lateral sclerosis	155/1791	364/8465	3.41e-21	1.13e-19	6.99e-20	155
hsa032503	Prostate	Tumor	Viral life cycle - HIV-1	25/1791	63/8465	6.13e-04	3.07e-03	1.91e-03	25

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

RANBP2

SNV

Missense_Mutation

c.2421G>C

p.Gln807His

p.Q807H

P49792

protein_coding

tolerated(0.07)

benign(0.045)

TCGA-A2-A0EQ-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

RANBP2

SNV

Missense_Mutation

c.2389C>G

p.Pro797Ala

p.P797A

P49792

protein_coding

deleterious(0)

benign(0.444)

TCGA-A7-A5ZX-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

doxorubicin

RANBP2

SNV

Missense_Mutation

c.8368N>C

p.Phe2790Leu

p.F2790L

P49792

protein_coding

tolerated(0.6)

benign(0)

TCGA-A8-A09A-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

RANBP2

SNV

Missense_Mutation

c.7958N>C

p.Leu2653Pro

p.L2653P

P49792

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-A8-A09Z-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

RANBP2

SNV

Missense_Mutation

c.3368N>G

p.Ser1123Cys

p.S1123C

P49792

protein_coding

tolerated(0.18)

benign(0.001)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

RANBP2

SNV

Missense_Mutation

novel

c.4334N>G

p.Asn1445Ser

p.N1445S

P49792

protein_coding

tolerated(0.34)

benign(0)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

RANBP2

SNV

Missense_Mutation

rs769492789

c.8032N>A

p.Glu2678Lys

p.E2678K

P49792

protein_coding

deleterious(0)

possibly_damaging(0.702)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

RANBP2

SNV

Missense_Mutation

novel

c.9362T>C

p.Val3121Ala

p.V3121A

P49792

protein_coding

deleterious(0.02)

benign(0.007)

TCGA-AN-A0FV-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

RANBP2

SNV

Missense_Mutation

novel

c.3164N>T

p.Pro1055Leu

p.P1055L

P49792

protein_coding

deleterious(0.01)

benign(0.245)

TCGA-AR-A2LR-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

RANBP2

SNV

Missense_Mutation

novel

c.6308G>C

p.Arg2103Thr

p.R2103T

P49792

protein_coding

deleterious(0)

possibly_damaging(0.754)

TCGA-AR-A5QQ-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

carboplatin

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1